HHS Drug Pricing Program Flouts Constitution, Boehringer Says

By Brian Steele · June 20, 2024, 5:42 PM EDT

An "unprecedented" new Medicare price negotiation program deprives drugmakers of their constitutional rights and forces them to make declarations on issues of public concern that reflect poorly on them, Boehringer Ingelheim...

To view the full article, register now.

Documents

Case Information

Case Title

Boehringer Ingelheim Pharmaceuticals, Inc. v. United States Department of Health and Human Services et al

Case Number

3:23-cv-01103

Court

Connecticut

Nature of Suit

Other Statutes: Administrative Procedures Act/Review or Appeal of Agency Decision

Date Filed

August 18, 2023